A Phase 2a, Proof of Concept, Open-label Study Evaluating the Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations
Phase of Trial: Phase II
Latest Information Update: 12 Oct 2018
At a glance
- Drugs Etrasimod (Primary)
- Indications Inflammatory bowel diseases
- Focus Proof of concept; Therapeutic Use
- Sponsors Arena Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 23 Mar 2018 Status changed from active, no longer recruiting to discontinued.
- 07 Nov 2017 According to an Arena Pharmaceuticals media release, status changed from recruiting to active, no longer recruiting.